Disclosures for "A Phase 3, Open-Label, Single-Arm, Multicenter Study to Evaluate Ravulizumab Administered Intravenously in Pediatric Patients With Anti-Acetylcholine Receptor Antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG)"
-
Dr. Niebler has received personal compensation for serving as an employee of Alexion. Dr. Niebler has stock in AstraZeneca.
-
Dr. Pandeya has nothing to disclose.
-
Dr. Chakravarty has received personal compensation for serving as an employee of Alexion-AstraZeneca Rare Disease. An immediate family member of Dr. Chakravarty has received personal compensation for serving as an employee of Beam Therapeutics. Dr. Chakravarty has stock in Alexion-Astrazeneca Rare Disease. An immediate family member of Dr. Chakravarty has stock in Beam Therapeutics.
-
Dr. Frick has received personal compensation for serving as an employee of AstraZeneca/Alexion Rare Disease. Dr. Frick has stock in AstraZeneca/Alexion Rare Disease.